Publication

Article

Oncology & Biotech News

December 2010
Volume4
Issue 12

ASH 2010: Elotuzumab Highly Active in Patients With Advanced Myeloma

Author(s):

The novel agent elotuzumab, when administered with lenalidomide (Revlimid) and dexamethasone, produced responses in 81% of previously treated myeloma patients.

The novel agent elotuzumab, when administered with lenalidomide (Revlimid) and dexamethasone, produced responses in 81% of previously treated myeloma patients, according to interim phase II study data presented at ASH 2010. Paul G. Richardson, MD, of Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, reported the findings.

Elotuzumab is a humanized monoclonal immunoglobin G1 antibody that targets CS1, a glycoprotein heavily expressed on the surface of multiple myeloma cells but with limited expression on normal cells. Phase I studies had demonstrated a high rate of response in patients with advanced disease, providing the rationale for the current phase II study. The primary objective of the open-label, multicenter trial is to select the maximum-tolerated dose.

The study included 63 patients whose disease had relapsed after or was refractory to 1 to 3 prior therapies; patients previously treated with lenalidomide were ineligible for the study. Richardson said 61% of patients had received ≥2 prior therapies, usually including bortezomib (Velcade) and/ or thalidomide, and more than three-quarters had undergone autologous transplantation.

Investigators randomized the patients to 28-day cycles of elotuzumab at a 10-mg/kg or 20-mg/kg dose, administered intravenously on days 1, 8, 15, and 22 of a 28-day cycle for the first 2 cycles Elotuzumab Highly Active in Patients With Advanced Myeloma and then on days 1 and 15 for subsequent cycles. Patients given both doses of elotuzumab received 25 mg of oral lenalidomide daily on days 1-21 and 40 mg of oral dexamethasone weekly. Treatment continued until disease progression or unacceptable toxicity. To mitigate possible infusion reactions, patients were pretreated with methylprednisolone, diphenhydramine or its equivalent; ranitidine or its equivalent; and acetaminophen. This regimen was administered 30 to 60 minutes prior to an elotuzumab infusion.

Among the 63 patients, a partial response or greater was observed in 51 (81%) patients, including 90% of those taking the lower, 10-mg dose. As a result of the response trend favoring the 10-mg dose, Richardson said the investigators selected this as the therapeutic dose for future evaluations. Overall, 5% of patients experienced complete response, which included 7% of patients in the 10-mg dosing arm. Nearly one-third (29%) of patients in the study had a very good partial response, and this increased to 32% of patients taking the 10-mg dose. In addition, 16% of patients study-wide achieved stable disease.

Prior treatment with thalidomide or bortezomib was not associated with weaker responses. In the 10-mg/kg dosing arm, the overall response rate was 90% for patients treated previously with thalidomide compared with an 83% overall response rate for patients who had taken bortezomib.

“The quality of the responses was very impressive as well,” said Richardson. “We saw a consistent signal in patients with prior thalidomide or bortezomib [use].” At a median follow-up of 4.9 months, the median progressionfree survival has not yet been reached.

Grade 3/4 toxicities were observed in 56% of patients, consisting primarily of muscle spasms, constipation, fatigue, pyrexia, and nausea. Richardson said toxicities were easily managed for most patients. Grade 3/4 hematologic toxicities were rare; 14% of patients developed neutropenia, another 14% experienced lymphopenia, and 13% experienced thrombocytopenia.

While 49% of patients had infusion reactions, only 1 patient had a grade 3 reaction. Richardson credited this to the effectiveness of the premedication regimen.

Richardson concluded that elotuzumab produced “robust and durable responses” in a population of patients who were highly refractory to existing therapies. He said the investigative drug will be further evaluated in a phase II trial expected to start in 2011.

_________________________________________________________________________

Richardson PG, Moreau P, Jakubowiak J, et al. Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: interim results of a phase 2 study. Presented at: 52nd ASH Annual Meeting and Exposition; December 4-7, 2010; Orlando, Florida.

Related Videos
Minoo Battiwalla, MD, MS
Farrukh Awan, MD, discusses treatment considerations with the use of pirtobrutinib in previously treated patients with hematologic malignancies.
Douglas W. Sborov, MD, MS
Meletios (Thanos) Dimopoulos, MD, professor, therapeutics, Hematology Oncology, National and Kapodistrian University of Athens School of Medicine
Michel Delforge, MD, PhD
Francine Foss, MD
Ashraf Z. Badros, MBCHB, professor, medicine, Medical Oncology, Hematology Oncology, University of Maryland Medical System
David C. Fisher, MD
Binod Dhakal, MD
Michel Delforge, MD, PhD, professor, Faculty of Medicine, Department of Hematology, director, member, Leuven Cancer Institute, member, Senior Academic Staff, Council of the Faculty of Medicine, Council of the Department of Oncology, University Hospital Leuven, University of Leuven